SBIR/STTR Research Award

Non-surgical treatment option for pelvic organ prolapse

Award identifier b06d6bfbca42105ab573f3685e82b99bdbdb320c556cb36f5d2bfcc8805124dcAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$2,989,644

Program and phase

SBIR · Phase II

Award year

2023

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
REIA LLC
Proposal award date
2023-05-11
Contract end date
2026-04-30
UEI
S4M9S99JS8J4
Solicitation number
PA22-177
Topic code
NICHD

Research abstract

Project Summary / Abstract Reia is working to address a prevalent gynecological condition, pelvic organ prolapse (POP), which affects more than 50% of women over the age of 50. POP occurs when the pelvic floor connective tissue and muscles weaken, allowing the uterus or vaginal walls to descend. In extreme cases, the uterus descends through the opening of the vagina and hangs outside of the body. POP can be treated non-surgically with a pessary that is inserted into the vagina and acts as a shelf to support the descending organs. Commonly used pessaries have a fixed and rigid design, making them difficult or impossible for patients to remove and insert independently. Reia has developed an innovative collapsible pessary to reduce pain and discomfort associated with pessary insertion and removal. During Phase II, the pessary successfully passed all FDA required mechanical, microbiological, and biocompatibility tests. Reia has evaluated its pessary in n=50 current pessary users between its early feasibility and feasibility trials. Subjects reported increased comfort during insertion and removal when using Reia’s pessary compared to their current pessaries and their prolapse was effectively supported. During Phase IIB, Reia will (1) prepare and submit a 510(k) clearance application to the FDA. Reia will achieve this aim by professionally manufacturing and testing fitting pessaries, performing packaging, shipping, and distribution testing, and compiling the 510(k) application. Reia will (2) modify and optimize a pessary applicator, which was designed during Phase II to increase access to self-management. To achieve this aim, Reia will professionally manufacture a ß-prototype with medical grade materials, perform benchtop mechanical, biocompatibility, and cleaning validation testing, and assemble a 510(k) application. Reia will (3) conduct a clinical trial comparing success of home-management between Reia’s pessary system (pessary and applicator) and the standard of care in pessary-naïve patients. Defined evaluation criteria have been established to measure progress and success. Reia’s founding team is comprised of a urogynecologist with 25 years of experience fitting pessaries and treating POP and a 3-person, female executive management team with combined experience in product development, operational manufacturing and production practices, and IP advisory. Additionally, an advisory board contributes expertise in urogynecology, commercialization of medical devices, and successful completion of numerous NIH grant funded projects. Reia has strategically aligned with manufacturing facilities, testing laboratories, and regulatory consultants to gain access to necessary equipment, resources, and guidance to successfully complete this project. Reia is committed to optimizing its pessary system for clinical use and manufacture to bring to market the first-ever pessary specifically designed to address women’s needs.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

3 SBIR/STTR records share this UEI (2018–2023). Reported award amounts total $5,185,645. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.